Semaglutide: A Promising Ally Against Alzheimer’s?

In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.

Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.

Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.

Rong xu

Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.

According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.

“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”

Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.

For more information, please contact Patty Zamora at [email protected].

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Portable Mortgages Could Rewrite the Housing Market

The Trump administration is considering letting homeowners take their low mortgage rates with them when they move—a major shift that could ease inventory shortages but disrupt mortgage‑backed securities and raise legal challenges.

Washington Fines Mortgage Broker Over $60K in Major Compliance Crackdown

Washington State regulators issued more than $62,650 in penalties, fees, and restitution to a mortgage broker after uncovering widespread violations, including inaccurate call reports, 79 webpages missing mandatory disclosures, prohibited advertising language, unregistered trade names, and improper borrower preapprovals. The case serves as a crucial reminder for all mortgage, real estate, insurance, and finance professionals to stay vigilant with compliance as oversight continues to tighten nationwide.

The Real Cost of Owning a Home in 2025: Zillow’s New Report Shows a Price Surge Buyers Can’t Ignore

Hidden homeownership expenses are climbing fast, with Zillow revealing that Americans now pay nearly $16,000 a year in taxes, insurance, and maintenance—up sharply from previous years. Soaring premiums, especially in Florida, and rising upkeep costs are reshaping affordability, slowing sales, and creating new challenges for both first-time buyers and seasoned homeowners.

US Commercial Insurance Rates Shift in 2025 as Most Premiums Rise and Workers’ Comp Drops

The latest Ivans Index reveals a mixed but meaningful shift in the 2025 commercial insurance landscape, with most major coverages—including commercial auto, general liability, BOP, property, and umbrella—experiencing year‑over‑year premium increases. Workers’ compensation remains the lone category trending downward. Rising claims costs, reinsurance pressures, and market capacity changes continue to drive rates upward, while Ivans’ new Benchmarks tool brings real‑time pricing intelligence to insurers. For real estate, insurance, mortgage, and business professionals, staying informed on these changes is key to planning, budgeting, and managing risk in the year ahead.

Mortgage Rates Dip as 50-Year Loan Proposal Sparks Big Market Reactions

This week’s mortgage update brought only a slight rate decline, but a much bigger conversation: the possibility of a 50-year mortgage. While a longer term could lower monthly payments by about $130 on a typical $400,000 loan, experts warn it would add more than $500,000 in extra interest and dramatically slow equity growth. With inflation still elevated and the Fed’s next moves uncertain, mortgage rates may edge higher heading into the season. Real estate and mortgage professionals should be ready to address client questions as this ultra-long loan idea gains attention, especially in markets like Florida where affordability remains tight.

LKP Finance’s Profit, Legal Battles, and Surprise Rebrand: A Wake‑Up Call for Today’s Professionals

LKP Finance reported a solid Rs 583.15‑lakh profit for Q2 2025 — but beneath the surface lies a storm of leadership changes, litigation over multi‑crore debts, a rare 12‑year‑old loan write‑back, and a full corporate transformation into Gyftr Limited. From compliance shake‑ups to a dramatic pivot into digital gifting and fintech, this quarter offers big lessons for professionals navigating fast‑evolving industries.